 Hung-Wen Yeh
Concepts (489)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain | 15 | 2022 | 80 | 1.820 |
Why?
| | Humans | 85 | 2024 | 6896 | 1.780 |
Why?
| | Female | 57 | 2024 | 3525 | 1.360 |
Why?
| | Adult | 35 | 2024 | 1181 | 1.170 |
Why?
| | Male | 45 | 2024 | 3337 | 1.060 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2024 | 9 | 1.050 |
Why?
| | Gestational Age | 8 | 2024 | 62 | 0.960 |
Why?
| | Machine Learning | 4 | 2020 | 17 | 0.930 |
Why?
| | Neuroimaging | 4 | 2021 | 18 | 0.920 |
Why?
| | Infant, Extremely Low Birth Weight | 2 | 2020 | 9 | 0.900 |
Why?
| | Adrenal Cortex Hormones | 1 | 2024 | 37 | 0.900 |
Why?
| | Infant, Premature, Diseases | 1 | 2023 | 22 | 0.850 |
Why?
| | Infant, Premature | 5 | 2023 | 85 | 0.840 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2023 | 40 | 0.810 |
Why?
| | Magnetic Resonance Imaging | 14 | 2022 | 122 | 0.810 |
Why?
| | Middle Aged | 25 | 2021 | 608 | 0.770 |
Why?
| | Infant, Newborn | 10 | 2024 | 816 | 0.770 |
Why?
| | Smoking Cessation | 4 | 2016 | 11 | 0.740 |
Why?
| | Infant | 9 | 2024 | 1446 | 0.710 |
Why?
| | Telemedicine | 1 | 2021 | 59 | 0.710 |
Why?
| | Mental Health | 4 | 2021 | 20 | 0.710 |
Why?
| | Anxiety Disorders | 6 | 2023 | 19 | 0.660 |
Why?
| | Motivation | 3 | 2021 | 16 | 0.640 |
Why?
| | Adolescent | 17 | 2023 | 2197 | 0.610 |
Why?
| | Heart Defects, Congenital | 3 | 2024 | 81 | 0.600 |
Why?
| | Birth Weight | 4 | 2023 | 28 | 0.600 |
Why?
| | Retrospective Studies | 12 | 2024 | 1296 | 0.590 |
Why?
| | Anxiety | 5 | 2023 | 51 | 0.580 |
Why?
| | Markov Chains | 2 | 2016 | 8 | 0.550 |
Why?
| | Research Design | 5 | 2020 | 63 | 0.540 |
Why?
| | Tobacco Use Disorder | 2 | 2012 | 2 | 0.520 |
Why?
| | Depressive Disorder, Major | 3 | 2020 | 14 | 0.510 |
Why?
| | Heart Rate, Fetal | 5 | 2013 | 5 | 0.500 |
Why?
| | Mental Disorders | 3 | 2021 | 16 | 0.500 |
Why?
| | Young Adult | 11 | 2022 | 647 | 0.500 |
Why?
| | Breast Neoplasms | 4 | 2017 | 38 | 0.470 |
Why?
| | Interoception | 2 | 2018 | 2 | 0.460 |
Why?
| | Awareness | 2 | 2018 | 4 | 0.460 |
Why?
| | Surveys and Questionnaires | 11 | 2023 | 274 | 0.460 |
Why?
| | Pregnancy | 9 | 2024 | 216 | 0.450 |
Why?
| | Glucose | 3 | 2014 | 22 | 0.450 |
Why?
| | Weight Loss | 4 | 2020 | 39 | 0.440 |
Why?
| | Longitudinal Studies | 8 | 2021 | 119 | 0.440 |
Why?
| | Child | 13 | 2024 | 3364 | 0.440 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2016 | 10 | 0.430 |
Why?
| | Motor Cortex | 4 | 2013 | 7 | 0.420 |
Why?
| | Kernicterus | 2 | 2023 | 7 | 0.420 |
Why?
| | Energy Intake | 2 | 2023 | 34 | 0.420 |
Why?
| | Stroke | 4 | 2013 | 22 | 0.420 |
Why?
| | Treatment Outcome | 10 | 2021 | 622 | 0.410 |
Why?
| | Body Mass Index | 5 | 2024 | 157 | 0.410 |
Why?
| | Depression | 4 | 2021 | 69 | 0.400 |
Why?
| | Osteochondrosis | 1 | 2011 | 1 | 0.400 |
Why?
| | Lidocaine | 1 | 2011 | 6 | 0.400 |
Why?
| | Knee Joint | 1 | 2011 | 3 | 0.400 |
Why?
| | Range of Motion, Articular | 1 | 2011 | 8 | 0.400 |
Why?
| | Pessimism | 2 | 2023 | 2 | 0.390 |
Why?
| | Energy Metabolism | 3 | 2023 | 26 | 0.390 |
Why?
| | Cognition | 3 | 2021 | 32 | 0.390 |
Why?
| | Pandemics | 2 | 2022 | 82 | 0.380 |
Why?
| | Education | 1 | 2010 | 3 | 0.370 |
Why?
| | Maternal Health Services | 1 | 2010 | 2 | 0.370 |
Why?
| | Breast Feeding | 1 | 2010 | 25 | 0.370 |
Why?
| | Adolescent Health Services | 1 | 2010 | 10 | 0.370 |
Why?
| | Health Education | 1 | 2010 | 26 | 0.360 |
Why?
| | Prospective Studies | 5 | 2023 | 525 | 0.360 |
Why?
| | Inflammation | 2 | 2022 | 51 | 0.360 |
Why?
| | Length of Stay | 3 | 2024 | 233 | 0.350 |
Why?
| | Brain Chemistry | 3 | 2016 | 4 | 0.350 |
Why?
| | Residence Characteristics | 2 | 2021 | 42 | 0.350 |
Why?
| | Exercise | 5 | 2024 | 140 | 0.340 |
Why?
| | Emotions | 2 | 2018 | 22 | 0.340 |
Why?
| | Neurons | 4 | 2013 | 19 | 0.340 |
Why?
| | Postoperative Complications | 2 | 2024 | 184 | 0.320 |
Why?
| | Double-Blind Method | 6 | 2022 | 44 | 0.320 |
Why?
| | Diet | 5 | 2023 | 52 | 0.300 |
Why?
| | DiGeorge Syndrome | 2 | 2022 | 8 | 0.290 |
Why?
| | Risk Assessment | 2 | 2022 | 137 | 0.290 |
Why?
| | Aged | 10 | 2018 | 378 | 0.280 |
Why?
| | Prefrontal Cortex | 2 | 2023 | 4 | 0.280 |
Why?
| | Biomarkers | 5 | 2022 | 136 | 0.270 |
Why?
| | Indians, North American | 3 | 2016 | 9 | 0.270 |
Why?
| | Hippocampus | 3 | 2016 | 3 | 0.270 |
Why?
| | C-Reactive Protein | 2 | 2022 | 16 | 0.260 |
Why?
| | Animals | 12 | 2016 | 729 | 0.260 |
Why?
| | Algorithms | 4 | 2019 | 105 | 0.250 |
Why?
| | Lumbar Vertebrae | 2 | 2015 | 12 | 0.250 |
Why?
| | Early Detection of Cancer | 2 | 2015 | 10 | 0.250 |
Why?
| | Quinolinic Acid | 2 | 2021 | 2 | 0.240 |
Why?
| | Laminectomy | 2 | 2014 | 3 | 0.240 |
Why?
| | Colorectal Neoplasms | 2 | 2015 | 29 | 0.240 |
Why?
| | Health Behavior | 3 | 2021 | 50 | 0.240 |
Why?
| | Feeding Behavior | 2 | 2015 | 50 | 0.240 |
Why?
| | Francisella tularensis | 3 | 2009 | 3 | 0.240 |
Why?
| | Emergency Service, Hospital | 2 | 2023 | 130 | 0.240 |
Why?
| | Motivational Interviewing | 1 | 2024 | 19 | 0.240 |
Why?
| | Cardiac Catheterization | 1 | 2024 | 20 | 0.240 |
Why?
| | Cephalometry | 1 | 2024 | 1 | 0.230 |
Why?
| | Hand Strength | 2 | 2013 | 7 | 0.230 |
Why?
| | Cardiac Surgical Procedures | 1 | 2024 | 30 | 0.230 |
Why?
| | Gyrus Cinguli | 1 | 2023 | 1 | 0.230 |
Why?
| | Acceleration | 1 | 2023 | 4 | 0.230 |
Why?
| | Wrist | 1 | 2023 | 3 | 0.230 |
Why?
| | Neuroglia | 3 | 2012 | 4 | 0.230 |
Why?
| | Hyperbilirubinemia, Neonatal | 1 | 2023 | 6 | 0.230 |
Why?
| | Dystonia | 1 | 2023 | 8 | 0.220 |
Why?
| | Brain Mapping | 3 | 2019 | 11 | 0.220 |
Why?
| | Reward | 2 | 2021 | 5 | 0.220 |
Why?
| | Counseling | 3 | 2012 | 28 | 0.220 |
Why?
| | Suicide | 1 | 2023 | 5 | 0.220 |
Why?
| | Laryngostenosis | 1 | 2022 | 1 | 0.220 |
Why?
| | Respiratory System Abnormalities | 1 | 2022 | 3 | 0.220 |
Why?
| | Fontan Procedure | 1 | 2023 | 19 | 0.210 |
Why?
| | Poverty | 3 | 2024 | 27 | 0.210 |
Why?
| | Child, Preschool | 4 | 2024 | 1569 | 0.210 |
Why?
| | Transcranial Direct Current Stimulation | 1 | 2022 | 1 | 0.210 |
Why?
| | Methamphetamine | 1 | 2022 | 2 | 0.210 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2022 | 7 | 0.210 |
Why?
| | Bayes Theorem | 5 | 2021 | 30 | 0.210 |
Why?
| | Acute Lung Injury | 1 | 2022 | 6 | 0.210 |
Why?
| | Extinction, Psychological | 1 | 2022 | 2 | 0.210 |
Why?
| | Breast | 2 | 2013 | 4 | 0.210 |
Why?
| | Abnormalities, Multiple | 1 | 2022 | 36 | 0.210 |
Why?
| | Sepsis | 1 | 2022 | 23 | 0.210 |
Why?
| | Firearms | 1 | 2022 | 7 | 0.200 |
Why?
| | Suicidal Ideation | 1 | 2022 | 6 | 0.200 |
Why?
| | Wounds, Gunshot | 1 | 2022 | 12 | 0.200 |
Why?
| | Transposition of Great Vessels | 1 | 2022 | 8 | 0.200 |
Why?
| | Methylphenidate | 1 | 2021 | 2 | 0.200 |
Why?
| | Cultural Diversity | 1 | 2021 | 2 | 0.200 |
Why?
| | Central Nervous System Stimulants | 1 | 2021 | 11 | 0.200 |
Why?
| | Respiration | 2 | 2012 | 5 | 0.200 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2021 | 18 | 0.200 |
Why?
| | Amygdala | 1 | 2021 | 3 | 0.200 |
Why?
| | Pediatric Obesity | 1 | 2024 | 137 | 0.190 |
Why?
| | Sex Characteristics | 1 | 2021 | 12 | 0.190 |
Why?
| | Behavior, Addictive | 1 | 2021 | 1 | 0.190 |
Why?
| | Growth Charts | 1 | 2021 | 3 | 0.190 |
Why?
| | Infant, Extremely Premature | 1 | 2021 | 14 | 0.190 |
Why?
| | Primary Health Care | 1 | 2021 | 42 | 0.190 |
Why?
| | Multifactorial Inheritance | 1 | 2021 | 17 | 0.190 |
Why?
| | Models, Statistical | 3 | 2017 | 29 | 0.190 |
Why?
| | Anticipation, Psychological | 1 | 2021 | 2 | 0.190 |
Why?
| | Autonomic Nervous System | 2 | 2012 | 9 | 0.190 |
Why?
| | Sleep | 1 | 2021 | 37 | 0.190 |
Why?
| | Kynurenine | 1 | 2020 | 1 | 0.190 |
Why?
| | Occupations | 1 | 2020 | 1 | 0.180 |
Why?
| | Feeding and Eating Disorders | 1 | 2020 | 8 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 55 | 0.180 |
Why?
| | Time Factors | 3 | 2024 | 250 | 0.180 |
Why?
| | Mindfulness | 1 | 2019 | 1 | 0.180 |
Why?
| | Logistic Models | 4 | 2014 | 84 | 0.170 |
Why?
| | Placental Insufficiency | 1 | 2019 | 1 | 0.170 |
Why?
| | Fetal Growth Retardation | 1 | 2019 | 2 | 0.170 |
Why?
| | Growth Disorders | 1 | 2019 | 25 | 0.170 |
Why?
| | Data Interpretation, Statistical | 2 | 2016 | 20 | 0.170 |
Why?
| | Asthma | 1 | 2022 | 157 | 0.170 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 336 | 0.170 |
Why?
| | Gray Matter | 1 | 2019 | 1 | 0.170 |
Why?
| | Optimism | 1 | 2019 | 2 | 0.170 |
Why?
| | Follow-Up Studies | 3 | 2021 | 304 | 0.170 |
Why?
| | Social Class | 1 | 2019 | 11 | 0.170 |
Why?
| | Mood Disorders | 1 | 2019 | 7 | 0.170 |
Why?
| | Movement | 1 | 2019 | 7 | 0.170 |
Why?
| | Aspartic Acid | 3 | 2014 | 3 | 0.160 |
Why?
| | Pain Measurement | 3 | 2017 | 45 | 0.160 |
Why?
| | Recovery of Function | 3 | 2015 | 17 | 0.160 |
Why?
| | Ibuprofen | 1 | 2018 | 1 | 0.160 |
Why?
| | Sensory Deprivation | 1 | 2018 | 1 | 0.160 |
Why?
| | Attention | 1 | 2018 | 13 | 0.150 |
Why?
| | T-Lymphocytes | 2 | 2008 | 31 | 0.150 |
Why?
| | Cerebral Cortex | 2 | 2015 | 6 | 0.150 |
Why?
| | Microbiota | 1 | 2018 | 8 | 0.150 |
Why?
| | Interferon-gamma | 2 | 2008 | 5 | 0.150 |
Why?
| | Behavior Therapy | 2 | 2015 | 35 | 0.150 |
Why?
| | Mass Screening | 2 | 2015 | 35 | 0.150 |
Why?
| | Age Factors | 4 | 2022 | 210 | 0.150 |
Why?
| | Socioeconomic Factors | 2 | 2021 | 53 | 0.150 |
Why?
| | Smoking | 3 | 2012 | 22 | 0.150 |
Why?
| | Nitriles | 1 | 2017 | 3 | 0.150 |
Why?
| | Cholecalciferol | 1 | 2017 | 3 | 0.150 |
Why?
| | Musculoskeletal Pain | 1 | 2017 | 5 | 0.150 |
Why?
| | Triazoles | 1 | 2017 | 3 | 0.150 |
Why?
| | Bone Density Conservation Agents | 1 | 2017 | 10 | 0.150 |
Why?
| | Low Back Pain | 1 | 2017 | 1 | 0.150 |
Why?
| | White Matter | 1 | 2017 | 6 | 0.150 |
Why?
| | Functional Neuroimaging | 2 | 2014 | 2 | 0.150 |
Why?
| | Diffusion Tensor Imaging | 1 | 2017 | 24 | 0.140 |
Why?
| | Rats | 5 | 2016 | 106 | 0.140 |
Why?
| | Paresis | 2 | 2013 | 2 | 0.140 |
Why?
| | Disease Progression | 5 | 2016 | 111 | 0.140 |
Why?
| | Liver | 2 | 2008 | 126 | 0.140 |
Why?
| | Risk Factors | 4 | 2023 | 487 | 0.140 |
Why?
| | Quality of Life | 2 | 2015 | 140 | 0.140 |
Why?
| | Weight Perception | 1 | 2016 | 2 | 0.140 |
Why?
| | Fetal Hypoxia | 1 | 2016 | 1 | 0.140 |
Why?
| | Corpus Striatum | 1 | 2016 | 2 | 0.140 |
Why?
| | Diet, High-Fat | 1 | 2016 | 3 | 0.140 |
Why?
| | Fear | 3 | 2022 | 17 | 0.140 |
Why?
| | Alzheimer Disease | 1 | 2016 | 1 | 0.130 |
Why?
| | Cerebral Amyloid Angiopathy | 1 | 2016 | 1 | 0.130 |
Why?
| | Amyloid beta-Peptides | 1 | 2016 | 2 | 0.130 |
Why?
| | Obesity | 2 | 2014 | 125 | 0.130 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2015 | 1 | 0.130 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 2 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 31 | 0.130 |
Why?
| | Exercise Test | 3 | 2023 | 17 | 0.130 |
Why?
| | Neural Pathways | 1 | 2015 | 5 | 0.130 |
Why?
| | Severity of Illness Index | 2 | 2016 | 149 | 0.130 |
Why?
| | Spinal Fusion | 1 | 2015 | 3 | 0.130 |
Why?
| | Transcriptome | 1 | 2015 | 59 | 0.120 |
Why?
| | Occult Blood | 1 | 2014 | 1 | 0.120 |
Why?
| | Intention | 1 | 2014 | 4 | 0.120 |
Why?
| | Colonoscopy | 1 | 2014 | 15 | 0.120 |
Why?
| | Pilot Projects | 4 | 2021 | 120 | 0.120 |
Why?
| | Social Support | 2 | 2014 | 25 | 0.120 |
Why?
| | Ki-67 Antigen | 2 | 2013 | 7 | 0.120 |
Why?
| | Patient Acceptance of Health Care | 1 | 2015 | 35 | 0.120 |
Why?
| | Weight Reduction Programs | 1 | 2014 | 25 | 0.120 |
Why?
| | Pain, Postoperative | 1 | 2015 | 35 | 0.120 |
Why?
| | Sex Factors | 3 | 2022 | 68 | 0.120 |
Why?
| | Neurochemistry | 1 | 2014 | 1 | 0.120 |
Why?
| | Skilled Nursing Facilities | 1 | 2014 | 1 | 0.120 |
Why?
| | Home Care Services | 1 | 2014 | 6 | 0.120 |
Why?
| | Aftercare | 1 | 2014 | 5 | 0.120 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 1 | 0.120 |
Why?
| | Tongue | 1 | 2013 | 1 | 0.120 |
Why?
| | Brain Ischemia | 1 | 2013 | 7 | 0.120 |
Why?
| | Exercise Therapy | 1 | 2013 | 5 | 0.120 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2013 | 3 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 28 | 0.120 |
Why?
| | Postmenopause | 1 | 2013 | 6 | 0.110 |
Why?
| | Case-Control Studies | 3 | 2022 | 215 | 0.110 |
Why?
| | Child Development Disorders, Pervasive | 1 | 2013 | 5 | 0.110 |
Why?
| | Amitriptyline | 1 | 2013 | 4 | 0.110 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2013 | 6 | 0.110 |
Why?
| | Docosahexaenoic Acids | 1 | 2013 | 3 | 0.110 |
Why?
| | Patient Discharge | 1 | 2014 | 57 | 0.110 |
Why?
| | Patient Compliance | 1 | 2013 | 55 | 0.110 |
Why?
| | Movement Disorders | 1 | 2013 | 4 | 0.110 |
Why?
| | Disease Models, Animal | 2 | 2013 | 71 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2013 | 25 | 0.110 |
Why?
| | Bilirubin | 2 | 2023 | 26 | 0.110 |
Why?
| | United States | 3 | 2022 | 669 | 0.110 |
Why?
| | Tularemia | 2 | 2009 | 2 | 0.110 |
Why?
| | Stochastic Processes | 1 | 2012 | 4 | 0.110 |
Why?
| | Brain Injuries | 1 | 2012 | 8 | 0.110 |
Why?
| | Sex Distribution | 1 | 2012 | 17 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2012 | 7 | 0.100 |
Why?
| | Self Efficacy | 1 | 2012 | 14 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2012 | 46 | 0.100 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2012 | 2 | 0.100 |
Why?
| | Disease Management | 1 | 2012 | 34 | 0.100 |
Why?
| | Mice | 5 | 2015 | 348 | 0.100 |
Why?
| | Hyperglycemia | 1 | 2012 | 13 | 0.100 |
Why?
| | Oxygen Consumption | 2 | 2023 | 18 | 0.100 |
Why?
| | Rural Population | 1 | 2012 | 42 | 0.100 |
Why?
| | Injections, Intra-Articular | 1 | 2011 | 1 | 0.100 |
Why?
| | Osmolar Concentration | 1 | 2011 | 6 | 0.100 |
Why?
| | Reference Values | 1 | 2011 | 39 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 35 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2011 | 38 | 0.100 |
Why?
| | Parents | 2 | 2024 | 157 | 0.100 |
Why?
| | Cultural Characteristics | 1 | 2011 | 2 | 0.100 |
Why?
| | Parasympathetic Nervous System | 1 | 2011 | 2 | 0.100 |
Why?
| | Diaphragm | 1 | 2011 | 6 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 94 | 0.100 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2011 | 3 | 0.100 |
Why?
| | Morphine | 1 | 2011 | 11 | 0.100 |
Why?
| | Narcotics | 1 | 2011 | 5 | 0.100 |
Why?
| | Kansas | 3 | 2019 | 43 | 0.100 |
Why?
| | Fetus | 1 | 2011 | 16 | 0.100 |
Why?
| | Butylene Glycols | 1 | 2010 | 1 | 0.090 |
Why?
| | Lignans | 1 | 2010 | 1 | 0.090 |
Why?
| | Phytoestrogens | 1 | 2010 | 2 | 0.090 |
Why?
| | Rats, Inbred F344 | 3 | 2016 | 3 | 0.090 |
Why?
| | Postoperative Period | 2 | 2024 | 18 | 0.090 |
Why?
| | Receptors, Dopamine D4 | 1 | 2010 | 1 | 0.090 |
Why?
| | Minisatellite Repeats | 1 | 2010 | 2 | 0.090 |
Why?
| | Alcoholism | 1 | 2010 | 4 | 0.090 |
Why?
| | Exons | 1 | 2010 | 34 | 0.090 |
Why?
| | Self Report | 2 | 2022 | 42 | 0.090 |
Why?
| | Academic Medical Centers | 1 | 2009 | 11 | 0.090 |
Why?
| | Caspase 3 | 1 | 2009 | 3 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2010 | 90 | 0.090 |
Why?
| | Anthropometry | 2 | 2023 | 15 | 0.090 |
Why?
| | Apoptosis | 1 | 2009 | 52 | 0.080 |
Why?
| | Inpatients | 1 | 2009 | 44 | 0.080 |
Why?
| | Protons | 3 | 2014 | 6 | 0.080 |
Why?
| | Carcinoma in Situ | 1 | 2009 | 1 | 0.080 |
Why?
| | Carcinoma, Ductal | 1 | 2009 | 2 | 0.080 |
Why?
| | Tetanus Toxoid | 1 | 2008 | 2 | 0.080 |
Why?
| | Candida | 1 | 2008 | 3 | 0.080 |
Why?
| | Antigens, Fungal | 1 | 2008 | 10 | 0.080 |
Why?
| | Antigens, Bacterial | 1 | 2008 | 9 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2008 | 58 | 0.080 |
Why?
| | Bacterial Vaccines | 1 | 2008 | 2 | 0.080 |
Why?
| | Granuloma | 1 | 2008 | 4 | 0.080 |
Why?
| | Vaccines, Attenuated | 1 | 2008 | 8 | 0.080 |
Why?
| | Killer Cells, Natural | 1 | 2008 | 13 | 0.080 |
Why?
| | Students | 2 | 2019 | 34 | 0.080 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2018 | 12 | 0.080 |
Why?
| | Toll-Like Receptor 2 | 1 | 2007 | 4 | 0.080 |
Why?
| | Magnetocardiography | 3 | 2013 | 3 | 0.070 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 99 | 0.060 |
Why?
| | Oklahoma | 2 | 2018 | 10 | 0.060 |
Why?
| | Aging | 2 | 2016 | 39 | 0.060 |
Why?
| | Respiration, Artificial | 1 | 2024 | 17 | 0.060 |
Why?
| | Health Promotion | 1 | 2024 | 39 | 0.060 |
Why?
| | Postoperative Care | 1 | 2024 | 30 | 0.060 |
Why?
| | Nigeria | 1 | 2023 | 3 | 0.060 |
Why?
| | Thinking | 1 | 2023 | 2 | 0.060 |
Why?
| | Accelerometry | 1 | 2023 | 47 | 0.060 |
Why?
| | Exercise Tolerance | 1 | 2023 | 7 | 0.050 |
Why?
| | Oxygen | 1 | 2023 | 14 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2023 | 16 | 0.050 |
Why?
| | Tertiary Healthcare | 1 | 2023 | 4 | 0.050 |
Why?
| | Hospitals | 1 | 2023 | 36 | 0.050 |
Why?
| | Mice, SCID | 2 | 2015 | 13 | 0.050 |
Why?
| | Cues | 1 | 2022 | 5 | 0.050 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 36 | 0.050 |
Why?
| | Demography | 1 | 2022 | 8 | 0.050 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2022 | 4 | 0.050 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2022 | 3 | 0.050 |
Why?
| | Prevalence | 1 | 2022 | 146 | 0.050 |
Why?
| | Safety | 1 | 2022 | 14 | 0.050 |
Why?
| | Insurance, Health | 1 | 2022 | 16 | 0.050 |
Why?
| | Medicine, Traditional | 1 | 2021 | 1 | 0.050 |
Why?
| | Body Composition | 1 | 2022 | 27 | 0.050 |
Why?
| | Heart Rate | 1 | 2022 | 26 | 0.050 |
Why?
| | Chronic Disease | 2 | 2012 | 105 | 0.050 |
Why?
| | Antidepressive Agents | 1 | 2021 | 20 | 0.050 |
Why?
| | Attitude to Health | 1 | 2021 | 26 | 0.050 |
Why?
| | Missouri | 1 | 2022 | 81 | 0.050 |
Why?
| | Oxidative Stress | 1 | 2021 | 17 | 0.050 |
Why?
| | Adolescent Development | 1 | 2021 | 4 | 0.050 |
Why?
| | Executive Function | 1 | 2021 | 10 | 0.050 |
Why?
| | Psychopathology | 1 | 2021 | 1 | 0.050 |
Why?
| | Cities | 1 | 2021 | 10 | 0.050 |
Why?
| | Kynurenic Acid | 1 | 2020 | 1 | 0.050 |
Why?
| | Tryptophan | 1 | 2020 | 4 | 0.050 |
Why?
| | Immunohistochemistry | 2 | 2011 | 48 | 0.050 |
Why?
| | Body Weight | 1 | 2020 | 52 | 0.050 |
Why?
| | Hospitals, Pediatric | 1 | 2022 | 187 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 24 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2011 | 32 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 35 | 0.040 |
Why?
| | Universities | 1 | 2019 | 6 | 0.040 |
Why?
| | Stress, Psychological | 1 | 2019 | 32 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2020 | 199 | 0.040 |
Why?
| | Macrophages | 2 | 2009 | 4 | 0.040 |
Why?
| | Placebos | 1 | 2018 | 4 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2018 | 35 | 0.040 |
Why?
| | Sensation | 1 | 2018 | 1 | 0.040 |
Why?
| | Anti-Anxiety Agents | 1 | 2018 | 5 | 0.040 |
Why?
| | Self Concept | 1 | 2018 | 8 | 0.040 |
Why?
| | Multilevel Analysis | 1 | 2018 | 3 | 0.040 |
Why?
| | Sampling Studies | 1 | 2018 | 4 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 4 | 0.040 |
Why?
| | Calcium, Dietary | 1 | 2017 | 7 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2017 | 33 | 0.040 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2017 | 9 | 0.040 |
Why?
| | Administration, Oral | 1 | 2017 | 58 | 0.040 |
Why?
| | Prognosis | 1 | 2018 | 211 | 0.040 |
Why?
| | Vegetables | 1 | 2016 | 8 | 0.030 |
Why?
| | Fruit | 1 | 2016 | 10 | 0.030 |
Why?
| | Guinea Pigs | 1 | 2016 | 1 | 0.030 |
Why?
| | Random Allocation | 1 | 2016 | 7 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2016 | 10 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2016 | 32 | 0.030 |
Why?
| | Plaque, Amyloid | 1 | 2016 | 1 | 0.030 |
Why?
| | Data Accuracy | 1 | 2016 | 6 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2016 | 17 | 0.030 |
Why?
| | Age of Onset | 1 | 2016 | 28 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 4 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2015 | 7 | 0.030 |
Why?
| | Receptor, ErbB-2 | 1 | 2015 | 4 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2015 | 10 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2015 | 8 | 0.030 |
Why?
| | Up-Regulation | 1 | 2015 | 25 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2015 | 11 | 0.030 |
Why?
| | beta Catenin | 1 | 2015 | 9 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2016 | 151 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2015 | 31 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2015 | 44 | 0.030 |
Why?
| | Parietal Lobe | 1 | 2015 | 1 | 0.030 |
Why?
| | Transcription Factors | 1 | 2015 | 52 | 0.030 |
Why?
| | Gastric Bypass | 1 | 2015 | 8 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 65 | 0.030 |
Why?
| | Feedback, Psychological | 1 | 2014 | 1 | 0.030 |
Why?
| | Body Weights and Measures | 1 | 2014 | 2 | 0.030 |
Why?
| | Goals | 1 | 2014 | 6 | 0.030 |
Why?
| | Safety-net Providers | 1 | 2014 | 1 | 0.030 |
Why?
| | Computer-Assisted Instruction | 1 | 2014 | 3 | 0.030 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2014 | 4 | 0.030 |
Why?
| | Decision Making | 1 | 2015 | 23 | 0.030 |
Why?
| | Glutamic Acid | 1 | 2014 | 3 | 0.030 |
Why?
| | Choline | 1 | 2014 | 2 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 2 | 0.030 |
Why?
| | Impulsive Behavior | 1 | 2013 | 3 | 0.030 |
Why?
| | Medical Records | 1 | 2014 | 14 | 0.030 |
Why?
| | Needs Assessment | 1 | 2014 | 18 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2013 | 8 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2014 | 11 | 0.030 |
Why?
| | Forecasting | 1 | 2014 | 22 | 0.030 |
Why?
| | Biopsy, Fine-Needle | 1 | 2013 | 2 | 0.030 |
Why?
| | Adipokines | 1 | 2013 | 2 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2013 | 35 | 0.030 |
Why?
| | Comorbidity | 1 | 2014 | 56 | 0.030 |
Why?
| | Proteomics | 1 | 2013 | 24 | 0.030 |
Why?
| | Walking | 1 | 2014 | 34 | 0.030 |
Why?
| | Gene Expression | 1 | 2013 | 67 | 0.030 |
Why?
| | Motor Activity | 1 | 2013 | 33 | 0.030 |
Why?
| | Retreatment | 1 | 2013 | 1 | 0.030 |
Why?
| | Propylamines | 1 | 2013 | 4 | 0.030 |
Why?
| | Atomoxetine Hydrochloride | 1 | 2013 | 10 | 0.030 |
Why?
| | Fetal Blood | 1 | 2013 | 5 | 0.030 |
Why?
| | Maternal-Fetal Exchange | 1 | 2013 | 6 | 0.030 |
Why?
| | Erythrocytes | 1 | 2013 | 11 | 0.030 |
Why?
| | Functional Laterality | 1 | 2013 | 3 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 2013 | 6 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2013 | 18 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2013 | 16 | 0.030 |
Why?
| | Mitochondria | 1 | 2012 | 11 | 0.030 |
Why?
| | Regression Analysis | 1 | 2012 | 52 | 0.030 |
Why?
| | Blood-Brain Barrier | 1 | 2012 | 2 | 0.030 |
Why?
| | Biological Transport, Active | 1 | 2012 | 4 | 0.030 |
Why?
| | Glutathione | 1 | 2012 | 11 | 0.030 |
Why?
| | Kinetics | 1 | 2012 | 31 | 0.030 |
Why?
| | Respiratory Mechanics | 1 | 2012 | 2 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 50 | 0.030 |
Why?
| | Maternal Behavior | 1 | 2012 | 3 | 0.030 |
Why?
| | Acute Disease | 1 | 2012 | 79 | 0.020 |
Why?
| | Blood Glucose | 1 | 2012 | 61 | 0.020 |
Why?
| | Self-Help Groups | 1 | 2011 | 1 | 0.020 |
Why?
| | Varenicline | 1 | 2011 | 2 | 0.020 |
Why?
| | Quinoxalines | 1 | 2011 | 2 | 0.020 |
Why?
| | Nicotinic Agonists | 1 | 2011 | 3 | 0.020 |
Why?
| | Benzazepines | 1 | 2011 | 4 | 0.020 |
Why?
| | Bupropion | 1 | 2011 | 3 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 17 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 11 | 0.020 |
Why?
| | Viral Load | 1 | 2011 | 14 | 0.020 |
Why?
| | Macaca mulatta | 1 | 2011 | 24 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 71 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2011 | 41 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2011 | 53 | 0.020 |
Why?
| | Mammography | 1 | 2010 | 2 | 0.020 |
Why?
| | Premenopause | 1 | 2010 | 3 | 0.020 |
Why?
| | Progesterone | 1 | 2010 | 2 | 0.020 |
Why?
| | Hyperplasia | 1 | 2010 | 5 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2011 | 65 | 0.020 |
Why?
| | Estradiol | 1 | 2010 | 9 | 0.020 |
Why?
| | Testosterone | 1 | 2010 | 30 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 150 | 0.020 |
Why?
| | Mexican Americans | 1 | 2010 | 2 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2012 | 115 | 0.020 |
Why?
| | Gene Frequency | 1 | 2010 | 90 | 0.020 |
Why?
| | Organizational Case Studies | 1 | 2009 | 3 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2009 | 8 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2009 | 1 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 12 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2009 | 8 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2009 | 32 | 0.020 |
Why?
| | Cytokines | 1 | 2009 | 48 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2009 | 2 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 6 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2009 | 8 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2009 | 64 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 1 | 0.020 |
Why?
| | Antibodies, Bacterial | 1 | 2008 | 8 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2008 | 18 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2008 | 34 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2009 | 99 | 0.020 |
Why?
| | Genotype | 1 | 2010 | 410 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2008 | 5 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2008 | 3 | 0.020 |
Why?
| | Cell Death | 1 | 2008 | 4 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2008 | 7 | 0.020 |
Why?
| | Gene Deletion | 1 | 2008 | 13 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2008 | 20 | 0.020 |
Why?
| | Interleukin-12 Subunit p40 | 1 | 2007 | 1 | 0.020 |
Why?
| | Interleukin-12 Subunit p35 | 1 | 2007 | 1 | 0.020 |
Why?
| | Interleukin-12 | 1 | 2007 | 3 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2007 | 4 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2007 | 6 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2007 | 59 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2007 | 84 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2007 | 92 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|